Viracta Therapeutics, Inc. Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.809 USD | -95.66% | 0.00% | 0.00% |
04:42pm | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
May. 09 | Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe1st Jan change | Capi. | |
---|---|---|
+29.38% | 48.16B | |
-1.12% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.09% | 25.59B | |
-22.93% | 18.96B | |
+8.04% | 12.92B | |
+29.18% | 12.03B | |
-1.86% | 11.77B |
- Stock Market
- Equities
- VIRX Stock
- Stock
- News Viracta Therapeutics, Inc.
- Transcript : Sunesis Pharmaceuticals, Inc., Q3 2019 Earnings Call, Nov 12, 2019